Questions or concerns about cancer?Contact the Cancer Nurseline
Mon - Fri 9 am - 5 pmEmail
The ideal anti-cancer therapy would selectively eradicate tumours, whilst minimizing side effects to normal tissue. Systemic chemotherapy is aimed at killing cancer cells, but efficacy is poor, and collateral effects (destruction of immune cells, illness etc) can make its use unacceptable. To successfully address the issue of specifying therapeutics solely to tumours, it is necessary to identify unique tumour attributes that separate them from healthy cells.
To this end, we have shown that bacteria are naturally capable of achieving this, localising to and growing specifically in tumours / metastases following intravenous injection. Our research focuses on the use of non-disease causing bacteria, such as probiotic bacteria regularly eaten in yoghurts etc. We propose to develop chemotherapies that are activated by such bacteria growing in prostate tumours. The 'natural' nature of this strategy is such that advancement to clinical trial in prostate cancer patients is likely to be rapid.
Developing therapeutics which specifically target cancer cells and leave healthy cells unharmed is a difficult process. It has been shown that certain harmless bacteria are capable of localising to and growing in tumour tissue only. This project aims to develop a way of manipulating these bacteria to produce and release therapeutic agents thereby causing death of the tumour.
Irish Cancer Society, 43/45 Northumberland Road, Dublin, D04 VX65, IrelandTel +353 (0)1 2310 500 | firstname.lastname@example.orgCRO 20868; CHY 5863; CRA 20009502
© Irish Cancer Society 1999-2018